LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akcijų sąrašas・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

24.41 -0.89

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.2

Max

24.62

Pagrindiniai rodikliai
By Trading Economics
Pajamos	45M 72M
Pardavimai	14M 279M
P/E Sektoriaus vid.	15.955 108.767
Pelnas, tenkantis vienai akcijai	0.42
Pelno marža	25.761
Darbuotojai	653
EBITDA	7.3M 48M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+32.61% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	410M 4.2B
Ankstesnė atidarymo kaina	25.3
Ankstesnė uždarymo kaina	24.41

Naujienos nuotaikos

By Acuity

34%

66%

79 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

14.845 / N/A Palaikymas ir pasipriešinimas

ACADIA Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-01 23:35; UTC

Svarbiausios naujienos

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026-03-01 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026-03-01 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026-03-01 23:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026-03-01 23:39; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-01 23:39; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026-03-01 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026-03-01 23:24; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-01 23:24; UTC

Rinkos pokalbiai

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026-03-01 23:21; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-01 23:21; UTC

Rinkos pokalbiai

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026-03-01 23:19; UTC

Svarbiausios naujienos

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026-03-01 23:17; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026-03-01 23:14; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026-03-01 22:55; UTC

Svarbiausios naujienos

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026-03-01 22:54; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026-03-01 22:53; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026-03-01 22:38; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026-03-01 22:21; UTC

Uždarbis

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026-03-01 22:17; UTC

Rinkos pokalbiai

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026-03-01 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026-03-01 22:00; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026-03-01 21:40; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026-03-01 21:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026-03-01 21:30; UTC

Rinkos pokalbiai

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026-03-01 21:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026-03-01 21:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026-03-01 20:58; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026-03-01 20:40; UTC

Rinkos pokalbiai

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026-03-01 20:24; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

ACADIA Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

32.61% į viršų

12 mėnesių prognozė

Vidutinis 32.57 USD 32.61%

Aukščiausias 40 USD

Žemiausias 23 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ACADIA Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių ACADIA Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.845 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

79 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.